A Multicenter, Double-blind, Randomized, Placebo-controlled, 4-Armed Parallel Group Study to Evaluate the Efficacy of Zolmitriptan 0.5-, 2.5- and 5-mg Nasal Spray in the Treatment of Acute Migraine Headache in Adolescents

Trial Profile

A Multicenter, Double-blind, Randomized, Placebo-controlled, 4-Armed Parallel Group Study to Evaluate the Efficacy of Zolmitriptan 0.5-, 2.5- and 5-mg Nasal Spray in the Treatment of Acute Migraine Headache in Adolescents

Completed
Phase of Trial: Phase III

Latest Information Update: 10 Sep 2017

At a glance

  • Drugs Zolmitriptan (Primary)
  • Indications Migraine
  • Focus Registrational; Therapeutic Use
  • Acronyms TEENZ
  • Sponsors AstraZeneca
  • Most Recent Events

    • 10 Sep 2017 Results of a post hoc analysis (n= 656) evaluating the effect of baseline preventive medications on the safety and efficacy of Zolmitriptan Nasal Spray presented at the 2017 International Headache Society.
    • 07 Sep 2017 Trial design and post-hoc analysis data comparing placebo responders versus non-responders during single-blind placebo run-in period, presented at the 2017 International Headache Society.
    • 11 Jun 2017 Results assessing the effect of age on the effectiveness of zolmitriptan nasal spray in adolescent migraine, using age subgroups of younger (12-14 years) and older (15-17 years) adolescents, presented at the 59th Annual Scientific Meeting of the American Headache Society.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top